Toledo, Jb

List of Publications by Year
in descending order

94 papers	13,625 citations	26630 56 h-index	43889 91 g-index
98 all docs	98 docs citations	98 times ranked	17055 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
2	Stages of pTDPâ€43 pathology in amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 20-38.	5.3	820
3	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimerâ€™s Coordinating Centre. Brain, 2013, 136, 2697-2706.	7.6	609
4	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
5	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€"An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396
6	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
7	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.8	362
8	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Medicine, 2018, 15, e1002482.	8.4	336
9	White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain, 2016, 139, 1164-1179.	7.6	314
10	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica, 2014, 127, 423-439.	7.7	237
11	Dysregulation of the epigenetic landscape of normal aging in Alzheimerâ€™s disease. Nature Neuroscience, 2018, 21, 497-505.	14.8	236
12	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	7.6	228
13	Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e39216.	2.5	210
14	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathologica, 2014, 128, 423-437.	7.7	203
15	CSF biomarkers associated with disease heterogeneity in early Parkinsonâ€™s disease: the Parkinsonâ€™s Progression Markers Initiative study. Acta Neuropathologica, 2016, 131, 935-949.	7.7	190
16	Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinsonâ€™s disease. Brain, 2011, 134, 36-49.	7.6	187
17	Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i> -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
18	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.8	167

#	ARTICLE	IF	CITATIONS
19	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathologica, 2012, 123, 825-839.	7.7	164
20	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	7.7	161
21	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	9.0	161
22	Longitudinal change in CSF Tau and AÎ² biomarkers for up to 48Âmonths in ADNI. Acta Neuropathologica, 2013, 126, 659-670.	7.7	160
23	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimerâ€™s disease and tauopathies. Acta Neuropathologica, 2014, 128, 679-689.	7.7	158
24	Factors affecting AÎ² plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	7.7	151
25	Cognitive decline and reduced survival in<i>C9orf72</i>expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 163-169.	1.9	141
26	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-Î²1â€"42 and Ï„ Proteins as Alzheimer Disease Biomarkers. Clinical Chemistry, 2013, 59, 903-916.	3.2	139
27	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	5.2	138
28	Characterizing the human hippocampus in aging and Alzheimerâ€™s disease using a computational atlas derived from ex vivo MRI and histology. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4252-4257.	7.1	136
29	Patterns of coordinated cortical remodeling during adolescence and their associations with functional specialization and evolutionary expansion. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3527-3532.	7.1	130
30	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Research and Therapy, 2017, 9, 89.	6.2	129
31	Pathological Î±-synuclein distribution in subjects with coincident Alzheimerâ€™s and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	7.7	123
32	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€"42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	3.3	123
33	Sex and APOE Îµ4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	12.8	115
34	Heterogeneity of neuroanatomical patterns in prodromal Alzheimerâ€™s disease: links to cognition, progression and biomarkers. Brain, 2017, 140, aww319.	7.6	114
35	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	7.7	114
36	Cardiovascular risk factors, cortisol, and amyloidâ€Î² deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 483-489.	0.8	113

#	Article	IF	Citations
37	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimer's Research and Therapy, 2013, 5, 8.	6.2	113
38	High beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease. Neurobiology of Disease, 2014, 64, 60-65.	4.4	113
39	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. NeuroImage: Clinical, 2014, 4, 164-173.	2.7	112
40	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109
41	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 123, 395-407.	7.7	104
42	Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. Archives of Neurology, 2012, 69, 1018-25.	4.5	100
43	Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 45-51.	2.2	97
44	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.8	97
45	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. Journal of Alzheimer's Disease, 2014, 41, 441-451.	2.6	94
46	Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thrombosis and Haemostasis, 2008, 100, 699-704.	3.4	92
47	White matter lesions. Neurology, 2018, 91, e964-e975.	1.1	92
48	The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimer's and Dementia, 2021, 17, 89-102.	0.8	92
49	CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathologica, 2013, 126, 683-697.	7.7	90
50	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	9.0	87
51	Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Movement Disorders, 2009, 24, 1437-1444.	3.9	82
52	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 949-955.	1.9	82
53	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.8	79
54	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications, 2014, 2, 26.	5.2	77

#	Article	IF	Citations
55	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	2.6	67
56	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	7.7	65
57	TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Current Biology, 2017, 27, 3579-3590.e6.	3.9	63
58	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	7.7	60
59	Improved protocol for measurement of plasma Î²-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. , 2012, 8, 250-260.		56
60	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. PLoS ONE, 2013, 8, e70269.	2.5	50
61	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific Data, 2017, 4, 170140.	5.3	49
62	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	1.6	47
63	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiology of Aging, 2014, 35, 1473-1482.	3.1	43
64	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.1	42
65	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. PLoS ONE, 2013, 8, e55531.	2.5	41
66	Validation of the Erlangen Score Algorithm for the Prediction of the Development ofÂDementia due to Alzheimerâ€™s Disease inÂPre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	2.6	41
67	Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization. Journal of Neurosurgery, 2016, 125, 1068-1079.	1.6	41
68	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.7	38
69	Relationship between<i>APOE</i>Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. American Journal of Neuroradiology, 2016, 37, 1636-1642.	2.4	36
70	Identifying amyloid pathologyâ€“related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	2.4	35
71	Regional tractâ€specific white matter hyperintensities are associated withÂpatterns of agingâ€related brain atrophy via vascular risk factors, butÂalso independently. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 278-284.	2.4	35
72	Cerebrospinal fluid Î±â€synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1052-1062.	0.8	34

#	Article	IF	Citations
73	A Longitudinal Study of Total and Phosphorylated Î±-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1541-1553.	2.6	29
74	Lifestyle factors modify obesity risk linked to PPARG2 and FTO variants in an elderly population: a cross-sectional analysis in the SUN Project. Genes and Nutrition, 2013, 8, 61-67.	2.5	27
75	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology, 2014, 83, 502-509.	1.1	26
76	A comparison of AÎ² amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathologica, 2014, 128, 543-550.	7.7	26
77	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimer's Research and Therapy, 2014, 6, 36.	6.2	26
78	Inflammatory markers and imaging patterns of advanced brain aging in the general population. Brain Imaging and Behavior, 2020, 14, 1108-1117.	2.1	26
79	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology, 2016, 87, 1227-1234.	1.1	25
80	Can MRI screen for CSF biomarkers in neurodegenerative disease?. Neurology, 2013, 80, 132-138.	1.1	21
81	Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimer's and Dementia, 2017, 13, 770-777.	0.8	20
82	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	2.6	15
83	Role of brain infarcts in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2861-2868.	3.1	14
84	Impaired functional default mode network in patients with mild neurological Wilsonâ€™s disease. Parkinsonism and Related Disorders, 2016, 30, 46-51.	2.2	14
85	RETINAL NERVE FIBER LAYER IS ASSOCIATED WITH BRAIN ATROPHY IN MULTIPLE SCLEROSIS. Neurology, 2008, 71, 1747-1748.	1.1	11
86	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. journal of applied laboratory medicine, The, 2020, 5, 183-193.	1.3	10
87	A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease. Parkinsonism and Related Disorders, 2022, 97, 57-62.	2.2	9
88	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	9
89	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	1.6	5
90	A framework for informing segmentation of in vivo MRI with information derived from ex vivo imaging: Application in the medial temporal lobe. , 2016, 2016, 6014-6017.		2

#	Article	IF	Citations
91	ADCoC: Adaptive Distribution Modeling Based Collaborative Clustering for Disentangling Disease Heterogeneity from Neuroimaging Data. IEEE Transactions on Emerging Topics in Computational Intelligence, 2023, 7, 308-318.	4.9	1
92	P1â€268: ASSOCIATION OF OLFACTORY SCORE WITH LONGITUDINAL COGNITION AND NEUROPATHOLOGICAL DIAGNOSIS. Alzheimer's and Dementia, 2018, 14, P384.	0.8	0
93	Dataâ€driven approach reveals heterogeneity and regionâ€specific association of white matter hyperintensities with the APOE genotype. Alzheimer's and Dementia, 2020, 16, e037342.	0.8	0
94	Disentangling disease heterogeneity from neuroimaging data via adaptive distribution modelingâ€"based collaborative clustering. Alzheimer's and Dementia, 2021, 17, .	0.8	0